NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 47, 2013, Pages

  Skora, Lukasz ^a   Mestan, Jürgen ^b   Fabbro, Doriano ^b   Jahnke, Wolfgang ^b   Grzesiek, Stephan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BACTERIAL PROTEIN; BCR ABL PROTEIN; GNF 5 PROTEIN; IMATINIB; PROTEIN SH2; PROTEIN SH3; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ESCHERICHIA COLI; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; X RAY CRYSTALLOGRAPHY;

CML; HETERONUCLEAR NMR; PROTEIN DYNAMICS;

ALLOSTERIC REGULATION; BENZAMIDES; CARBON ISOTOPES; ESCHERICHIA COLI; FUSION PROTEINS, BCR-ABL; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MULTIPROTEIN COMPLEXES; NITROGEN ISOTOPES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PIPERAZINES; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SCATTERING, SMALL ANGLE;

EID: 84888104464     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314712110     Document Type: Article

References (58)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600-1912-1934
2. Pluk H, Dorey K, Superti-Furga G (2002) Autoinhibition of c-Abl. Cell 108(2-247-259
3. Nagar B, et al. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112(6-859-871
4. Hantschel O, et al. (2003) A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112(6-845-857
5. Nagar B, et al. (2006) Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 21(6-787-798
6. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247(4944-824-830
7. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340(17-1330-1340
8. Druker BJ, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5-561-566
9. Schindler T, et al. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486-1938-1942
10. Shah NP, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682-399-401
11. Weisberg E, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2-129-141
12. Gorre ME, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531-876-880
13. O'Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110(7- 2242-2249
14. Shah NP, et al. (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117(9-2562-2569
15. O'Hare T, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5-401-412
16. Chan WW, et al. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC- 2036. Cancer Cell 19(4-556-568
17. Thomas M, et al. (2011) Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett 21(12-3743-3748
18. Adrián FJ, et al. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2(2-95-102
19. Fabbro D, et al. (2010) Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochim Biophys Acta 1804(3-454-462
20. Zhang J, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463(7280-501-506
21. Jahnke W, et al. (2010) Binding or bending: Distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc 132(20-7043-7048
22. Yang J, et al. (2011) Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol 18(2- 177-186
23. Filippakopoulos P, et al. (2008) Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134(5-793-803
24. Filippakopoulos P, Müller S, Knapp S (2009) SH2 domains: Modulators of nonreceptor tyrosine kinase activity. Curr Opin Struct Biol 19(6-643-649
25. Grebien F, et al. (2011) Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 147(2-306-319
26. Grzesiek S, Sass H-J (2009) From biomolecular structure to functional understanding: New NMR developments narrow the gap. Curr Opin Struct Biol 19(5-585-595
27. Masterson LR, et al. (2011) Dynamically committed, uncommitted, and quenched states encoded in protein kinase A revealed by NMR spectroscopy. Proc Natl Acad Sci USA 108(17-6969-6974
28. Akimoto M, et al. (2013) Signaling through dynamic linkers as revealed by PKA. Proc Natl Acad Sci USA 110(35-14231-14236
29. Vogtherr M, et al. (2006) NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew Chem Int Ed Engl 45(6-993-997
30. Honndorf VS, Coudevylle N, Laufer S, Becker S, Griesinger C (2008) Dynamics in the p38alpha MAP kinase-SB203580 complex observed by liquid-state NMR spectroscopy. Angew Chem Int Ed Engl 47(19-3548-3551
31. Wiesner S, et al. (2006) A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases. EMBO J 25(19-4686-4696
32. Vajpai N, et al. (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283(26-18292-18302
33. Bax A, Grishaev A (2005) Weak alignment NMR: A hawk-eyed view of biomolecular structure. Curr Opin Struct Biol 15(5-563-570
34. Fushman D, Ghose R, Cowburn D (2000) The effect of finite sampling on the determination of orientational properties: A theoretical treatment with application to interatomic vectors in proteins. J Am Chem Soc 122(43-10640-10649
35. Sass J, et al. (1999) Purple membrane induced alignment of biological macromolecules in the magnetic field. J Am Chem Soc 121(10-2047-2055
36. Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM (2003) The Xplor-NIH NMR molecular structure determination package. J Magn Reson 160(1-65-73
37. Grishaev A, Wu J, Trewhella J, Bax A (2005) Refinement of multidomain protein structures by combination of solution small-angle X-ray scattering and NMR data. J Am Chem Soc 127(47-16621-16628
38. Schwieters CD, et al. (2010) Solution structure of the 128 kDa enzyme I dimer from Escherichia coli and its 146 kDa complex with HPr using residual dipolar couplings and small- and wide-angle X-ray scattering. J Am Chem Soc 132(37-13026-13045
39. Nagar B, et al. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62(15- 4236-4243
40. Selvaratnam R, Chowdhury S, VanSchouwen B, Melacini G (2011) Mapping allostery through the covariance analysis of NMR chemical shifts. Proc Natl Acad Sci USA 108(15-6133-6138
41. Hantschel O, Superti-Furga G (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5(1-33-44
42. Brasher BB, Van Etten RA (2000) c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275(45-35631-35637
43. Panjarian S, et al. (2013) Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors. J Biol Chem 288(9-6116-6129
44. McWhirter JR, Galasso DL, Wang JY (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13(12-7587-7595
45. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5(3-172-183
46. Barilá D, Superti-Furga G (1998) An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 18(3-280-282
47. Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112(6-831-843
48. Sherbenou DW, et al. (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116(17-3278-3285
49. Salzmann M, Wider G, Pervushin K, Senn H, Wuthrich K (1999) TROSY-type tripleresonance experiments for sequential NMR assignments of large proteins. J Am Chem Soc 121(4-844-848
50. Vajpai N, et al. (2008) Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib. Biomol NMR Assign 2(1-41-42
51. Xu R, Cahill S, Cowburn D (1999) Triple resonance-based assignment for Abl SH(32) and its complex with a consolidated ligand. J Biomol NMR 14(2-187-188
52. Kay LE, Torchia DA, Bax A (1989) Backbone dynamics of proteins as studied by 15N inverse detected heteronuclear NMR spectroscopy: Application to staphylococcal nuclease. Biochemistry 28(23-8972-8979
53. Delaglio F, et al. (1995) NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6(3-277-293
54. Goddard T, Kneller D (2008) SPARKY 3 (Univ of California, San Francisco).
55. Fitzkee NC, Bax A (2010) Facile measurement of H-5N residual dipolar couplings in larger perdeuterated proteins. J Biomol NMR 48(2-65-70
56. Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, Svergun DI (2003) PRIMUS: A Windows PC-based system for small-angle scattering data analysis. J Appl Crystallogr 36(5-1277-1282
57. Svergun DI (1992) Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J Appl Crystallogr 25(4-495-503
58. Manley PW, et al. (2008) Rational design of T315I BCR-Abl inhibitors for the treatment of drug-resistant chronic myelogenous leukemia (CML- BGG463. Chimia (Aarau) 62(7-8-579.